Resultados de búsqueda - David Irwin

Limitar resultados
  1. 1
    The Splenic Syndrome in Individuals with Sickle Cell Trait

    The Splenic Syndrome in Individuals with Sickle Cell Trait por Jessica Goodman, Kathryn Hassell, David Irwin, Ewa H. Witkowski, Rachelle Nuss

    Publicado 2014
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  2. 2
    RhoGTPase in Vascular Disease

    RhoGTPase in Vascular Disease por Derek Strassheim, Evgenia Gerasimovskaya, David Irwin, Edward C. Dempsey, Kurt R. Stenmark, Vijaya Karoor

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  3. 3
    Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer

    Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer por Mohammad Jahanzeb, Joanne Mortimer, Furhan Yunus, David Irwin, James L. Speyer, Alan J. Koletsky, Paula Klein, Tariq Sabir, Lori Kronish

    Publicado 2002
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    A Single-Center Experience with a Shear-Thinning Conformable Embolic

    A Single-Center Experience with a Shear-Thinning Conformable Embolic por Koustav Pal, Milan Patel, Stephen Chen, Bruno C. Odisio, Zeyad Metwalli, Judy U. Ahrar, David Irwin, Rahul A. Sheth, J. Kuban

    Publicado 2024
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease

    Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease por Ayla Yalamanoglu, Jeremy W. Deuel, Ryan Hunt, Jin Hyen Baek, Kathryn L. Hassell, Katie Redinius, David Irwin, Dominik J. Schaer, Paul W. Buehler

    Publicado 2018
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Nrf2 activation: A potential strategy for the prevention of acute mountain sickness

    Nrf2 activation: A potential strategy for the prevention of acute mountain sickness por Christina Lisk, Joe M. McCord, Swapan K. Bose, Timothy J. Sullivan, Zoe Loomis, Eva Nozik‐Grayck, Thies Schroeder, Karyn L. Hamilton, David Irwin

    Publicado 2013
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dose haptoglobin administration

    Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dos... por David Irwin, Jin Hyen Baek, Kathryn L. Hassell, Rachelle Nuss, Paul Eigenberger, Christina Lisk, Zoe Loomis, Joanne Maltzahn, Kurt R. Stenmark, Eva Nozik‐Grayck, Paul W. Buehler

    Publicado 2015
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

    Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma por Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, Eli Gabayan, Amitabha Mazumder, David P. Schenkein, John Crowley

    Publicado 2005
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

    Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma por Paul G. Richardson, Bart Barlogie, James R. Berenson, Seema Singhal, Sundar Jagannath, David Irwin, S. Vincent Rajkumar, Teru Hideshima, Hugh Xiao, Dixie Esseltine, David P. Schenkein, Kenneth C. Anderson

    Publicado 2005
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study

    Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study por Stephanie J. Lee, Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Jesús F. San Miguel, Bruce Crawford, Joseph M. Massaro, Ravinder Dhawan, Sanjay Gupta, Kenneth C. Anderson

    Publicado 2008
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism

    Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism por Paul W. Buehler, Jin Hyen Baek, Christina Lisk, Ian Connor, Timothy J. Sullivan, Douglas J. Kominsky, Susan M. Majka, Kurt R. Stenmark, Eva Nozik‐Grayck, J. Bonaventura, David Irwin

    Publicado 2012
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma

    Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma por Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, Phyllis Potts, Afshin Eli Gabayan, Amitabha Mazumder, John Crowley, Robert Vescio

    Publicado 2009
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  13. 13
    Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension

    Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension por Douglas D. Lemon, Todd R. Horn, Maria A. Cavasin, Mark Y. Jeong, Kurt Haubold, Carlin S. Long, David Irwin, Sylvia A. McCune, Eunhee Chung, Leslie A. Leinwand, Timothy A. McKinsey

    Publicado 2011
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  14. 14
    Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

    Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial por Meinolf Karthaus, Albrecht Kretzschmar, H. Kröning, M. Biakhov, David Irwin, Norbert Marschner, C. Slabber, George Fountzilas, A. Garin, N.G.F. Abecasis, W. Baronius, G. Steger, T Südhoff, C. Giorgetti, Peter Reichardt

    Publicado 2005
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  15. 15
    Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma

    Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma por Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Façon, Jean‐Luc Harousseau, Dina Ben‐Yehuda, Sagar Lonial, Jesús F. San Miguel, Jamie Cavenagh, Kenneth C. Anderson

    Publicado 2007
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  16. 16
    Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension

    Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension por Eva Nozik‐Grayck, Crystal Woods, Joann M. Taylor, Richard K.P. Benninger, R. Daniel Johnson, Leah R. Villegas, Kurt R. Stenmark, David G. Harrison, Susan M. Majka, David Irwin, Kathryn N. Farrow

    Publicado 2014
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  17. 17
    A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

    A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma por Sundar Jagannath, Bart Barlogie, James R. Berenson, David S. Siegel, David Irwin, Paul G. Richardson, Rubén Niesvizky, Raymond Alexanian, Steven Limentani, Melissa Alsina, Julian Adams, Michael Kauffman, Dixie‐Lee Esseltine, David P. Schenkein, Kenneth C. Anderson

    Publicado 2004
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  18. 18
    The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

    The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multip... por Rubén Niesvizky, Paul G. Richardson, S. Vincent Rajkumar, Morton Coleman, Laura Rosiñol, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Façon, Jean‐Luc Harousseau, Anthony Boral, Dixie‐Lee Esseltine, Kenneth C. Anderson, Joan Bladé

    Publicado 2008
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  19. 19
    A potential role for reactive oxygen species and the HIF-1α–VEGF pathway in hypoxia-induced pulmonary vascular leak

    A potential role for reactive oxygen species and the HIF-1α–VEGF pathway in hypoxia-induced pulmonary vascular leak por David Irwin, Joe M. McCord, Eva Nozik‐Grayck, Ginny Beckly, Ben Foreman, Timothy J. Sullivan, Molly White, Joseph T. Crossno, Damian M. Bailey, Sonia C. Flores, Susan M. Majka, Dwight J. Klemm, Martha C. Tissot van Patot

    Publicado 2009
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  20. 20
    Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

    Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma por Paul G. Richardson, Sundar Jagannath, Mohamad A. Hussein, James R. Berenson, Seema Singhal, David Irwin, Stephanie Williams, William Bensinger, Ashraf Badros, Robert Vescio, Laurie Kenvin, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight, Kenneth C. Anderson

    Publicado 2009
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: